Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate
Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate
Aytu BioPharma 2024年第二季度GAAP每股收益（0.04美元）超過預期（0.25美元），銷售額2,293萬美元超過2175萬美元的預期
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. The company reported quarterly sales of $22.93 million which beat the analyst consensus estimate of $21.75 million by 5.47 percent. This is a 12.73 percent decrease over sales of $26.28 million the same period last year.
艾圖生物製藥（納斯達克股票代碼：AYTU）公佈的季度虧損爲每股0.04美元，比分析師普遍預期的0.25美元（0.25美元）高出84％。該公司公佈的季度銷售額爲2,293萬美元，比分析師普遍預期的2175萬美元高出5.47％。這比去年同期的2628萬美元銷售額下降了12.73％。